Mortality Risk of Patients Treated in Dialysis Facilities with Payment Reductions under ESRD Quality Incentive...

Area of Science:

• Nephrology
• Health Services Research
• Public Health Policy

Background:

• The End-Stage Renal Disease Quality Incentive Program (ESRD QIP) by the Centers for Medicare & Medicaid Services aims to improve dialysis facility care quality.
• Payment reductions are imposed on facilities with quality lapses, but the impact on patient mortality, a key quality indicator, remains under-examined.

Purpose of the Study:

• To investigate the association between ESRD QIP facility payment reductions and patient mortality.
• To determine if a dose-response relationship exists between the level of payment reduction and mortality rates.

Main Methods:

• Retrospective analysis of patient cohorts treated at dialysis facilities from 2010 to 2018.
• Examined the association between facility payment reduction levels (0% to 2%) and patient mortality, adjusting for patient case-mix.
• Assessed the relationship between 1-year changes in payment reductions and subsequent mortality.

Main Results:

• A significant association was found between higher ESRD QIP payment reduction levels and increased patient mortality.
• Unadjusted mortality rates rose progressively with payment reduction levels, from 17.3 to 23.9 deaths per 100 patient-years.
• Adjusted hazard ratios indicated a stepwise increase in mortality risk with higher payment reductions, reaching 1.34 for the highest reduction level.
• The strength of this association intensified between 2010 and 2016.

Conclusions:

• Patient mortality is demonstrably associated with ESRD QIP facility payment reductions.
• The observed dose-response and temporal patterns highlight the critical link between quality metrics, financial incentives, and patient survival in dialysis care.